Recombinant Vaccines for Prevention of AIDS and Other Diseases

Moss, Bernard

Abstract

There are many diseases for which there are no vaccines and others for which the vaccines are not optimal or have significant side effects. The objectives of this project are to develop new vectors, characterize viral antigens, determine targets of humoral and cell mediated immunity, and use this information to develop candidate vaccines. Live recombinant viral vaccines, DNA vaccines and recombinant protein vaccines are being developed. Presently we are working on vaccinia virus-vectored vaccines for HIV. The vaccines are first tested in small animals and then in non-human primates. Phase 1 and 2 clinical trials are ongoing by collaborators.

Funding Agency

• Agency: National Institute of Health (NIH)
• Institute: National Institute of Allergy and Infectious Diseases (NIAID)
• Type: Investigator-Initiated Intramural Research Projects (ZIA)
• Project #: 1ZIAAI000416-33
• Application #: 9354703
• Support Year: 33
• Fiscal Year: 2016

Institution

• Name: Niaid Extramural Activities

Publications

Hu, Xintao; Valentin, Antonio; Cai, Yanhui et al. (2018) DNA Vaccine-Induced Long-Lasting Cytotoxic T Cells Targeting Conserved Elements of Human Immunodeficiency Virus Gag Are Boosted Upon DNA or Recombinant Modified Vaccinia Ankara Vaccination. Hum Gene Ther :

Baden, Lindsey R; Walsh, Stephen R; Seaman, Michael S et al. (2018) First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector. J Infect Dis 218:633-644

Jones, Andrew T; Chamcha, Venkateswarlu; Kesavardhana, Sannula et al. (2018) A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques. J Virol 92:

Gangadhara, Sailaja; Kwon, Young-Man; Jeeva, Subbiah et al. (2017) Vaccination with Combination DNA and Virus-Like Particles Enhances Humoral and Cellular Immune Responses upon Boost with Recombinant Modified Vaccinia Virus Ankara Expressing Human Immunodeficiency Virus Envelope Proteins. Vaccines (Basel) 5:

Wyatt, Linda S; Xiao, Wei; Americo, Jeffrey L et al. (2017) Novel Nonreplicating Vaccinia Virus Vector Enhances Expression of Heterologous Genes and Suppresses Synthesis of Endogenous Viral Proteins. MBio 8:

Ake, Julie A; Schuetz, Alexandra; Pegu, Poonam et al. (2017) Safety and Immunogenicity of PENNVAX-G DNA Prime Administered by Biojector 2000 or CELLECTRA Electroporation Device With Modified Vaccinia Ankara-CMDR Boost. J Infect Dis 216:1080-1090

Hinkula, J; Petkov, S; Ljungberg, K et al. (2017) HIVIS-DNA or HIVISopt-DNA priming followed by CMDR vaccinia-based boosts induce both humoral and cellular murine immune responses to HIV. Heliyon 3:e00339

Joachim, Agricola; Munseri, Patricia J; Nilsson, Charlotta et al. (2017) Three-Year Durability of Immune Responses Induced by HIV-DNA and HIV-Modified Vaccinia Virus Ankara and Effect of a Late HIV-Modified Vaccinia Virus Ankara Boost in Tanzanian Volunteers. AIDS Res Hum Retroviruses 33:880-888

Shen, Xiaoying; Basu, Rahul; Sawant, Sheetal et al. (2017) HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine. J Virol 91:

Wyatt, Linda S; Earl, Patricia L; Moss, Bernard (2017) Generation of Recombinant Vaccinia Viruses. Curr Protoc Mol Biol 117:16.17.1-16.17.18